Does treatment of cadaveric organ donors with desmopressin increase the likelihood of pancreas graft thrombosis? results of a preliminary study
| Autor: | Kenneth D. Chavin, P. R. Rajagopalan, Elizabeth E. Ashcraft, Fuad Afzal, R.G Marques, Angello Lin, Osemwegie E. Emovon, G.M. Baillie, Jeffrey Rogers, P.K. Baliga, D.J. Taber |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Pancreas transplantation urologic and male genital diseases Animal data Postoperative Complications Cadaver medicine Humans Deamino Arginine Vasopressin Clinical significance Prospective cohort study Desmopressin Pancreas Retrospective Studies Transplantation business.industry Thrombosis medicine.disease Tissue Donors Surgery Diabetes insipidus Female Pancreas Transplantation business hormones hormone substitutes and hormone antagonists Follow-Up Studies medicine.drug |
| Zdroj: | Transplantation Proceedings. 36:1048-1049 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/j.transproceed.2004.04.043 |
| Popis: | Desmopressin (DDAVP) is commonly used in cadaveric organ donors to treat diabetes insipidus. The thrombogenic potential of DDAVP is well known. Recent animal data have demonstrated that DDAVP impairs pancreas graft (PG) microcirculation and perfusion. The aim of this study was too evaluate the effect of DDAVP on the incidence of PG thrombosis in clinical pancreas transplantation. A retrospective review of simultaneous kidney–pancreas transplant (SKPT) entered in the Scientific Registry of Transplant Recipients (SRTR) between 10/5/87 and 9/27/02 was performed. Patients were included for analysis if there was definitive documentation as to whether DDAVP was (DDAVP-Y) or was not (DDAVP-N) administered to the donor. Both dose and duration of DDAVP treatment were not recorded by SRTR. A total of 2804 SKPTs were available for analysis. Mean follow-up was 1.75 years (range, 1 month to 8.4 years). A total of 1287 SKPT patients (46%) received a PG from a DDAVP-Y donor. Graft ischemia times, donor and recipient ages, recipient gender distribution, surgical techniques, and immunosuppressive regimens were similar in both groups. The overall incidence of PG thrombosis was 4.3%. The incidence of PG thrombosis in recipients of grafts from DDAVP-Y donors was 5.1% compared to 3.5% in recipients of grafts from DDAVP-N donors ( P = .04). Fifty-eight percent of thrombosed PG came from DDAVP-Y donors compared to 42% from DDAVP-N donors ( P = .04). We conclude that there appears to be a relationship between donor treatment with DDAVP and PG thrombosis. A prospective study is needed to verify these findings and to determine their clinical significance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect